Visual impairment may have a role in dementia, according to a new study

News
Article

Visual impairment has been consistently identified as a “robust risk factor” in the development of dementia.

MRI scan results Image credit: AdobeStock/Atthapon

Image credit: AdobeStock/Atthapon

A recent cross-sectional study1 found about 19% of dementia prevalence might have resulted from visual impairments that are largely correctable, according to first author Jason R. Smith, ScM, from the Department of Epidemiology and the Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.

He and his colleagues advocated prevention and treatment of visual impairments, ie, distance and near visual acuity and contrast sensitivity, to lower the prevalence rate of dementia.

The investigators explained that because the prevalence rate of dementia is rising global, addressing modifiable risk factors is a priority for preventing the disease.2-4 Visual impairment has been consistently identified as a “robust risk factor” in the development of dementia.5-8 Because vision impairment affects up to 28% of those older than 70 years,9,10 the proportion of dementia resulting from vision impairment might be considerable.

The researchers conducted this population-based cross-sectional analysis in the National Health and Aging Trends Study,11 which gathers nationally representative information in the US on Medicare beneficiaries aged 65 years and older. A total of 2767 community-dwelling adults were included.

The main outcomes were the adjusted population attributable fractions (PAFs) (defined as a measure of how much a risk factor contributes to disease or death in a population) of prevalent dementia, defined using a standardized algorithmic diagnosis (≥1.5 standard deviations below the mean on 1 or more cognitive domains, self- or proxy-reported dementia diagnosis, or the Ascertain Dementia-8 Dementia Screening Interview Score of probable dementia.

Mr. Smith and colleagues reported that the survey-weighted prevalence of vision impairment among participants aged 71 and older was 32.2%. The participants were 54.7% female, 8.0% non-Hispanic Black, 81.7% Hispanic, 81.7% non-Hispanic White, and 3.3% non-Hispanic other.

“The PAF of prevalent dementia from at least 1 vision impairment was 19.0% (95% confidence interval [CI], 8.2-29.7). Contrast sensitivity impairment yielded the strongest attributable fraction among all impairments (15.0%; 95% CI, 6.6-23.6), followed by near acuity (9.7%; 95% CI, 2.6-17.0), and distance acuity (4.9%; 95% CI, 0.1-9.9). PAFs from at least 1 visual impairment were highest among participants aged 71 to 79 years (24.3%; 95% CI, 6.6-41.8), female (26.8%; 95% CI, 12.2-39.9), and non-Hispanic White (22.3%; 95% CI, 9.6-34.5) subpopulations, with estimates consistent across educational strata,” the authors reported.

They commented that the PAFs of dementia from vision impairments ranged from 4.9% to 19.0%; however, although this is not a cause-and-effect relationship, “these findings support inclusion of multiple objective measures of vision impairments, including contrast sensitivity and visual acuity, to capture the total potential impact of addressing vision impairment on dementia.”

Because contrast sensitivity was associated with the largest PAF, this indicated that the total impact of vision impairment on dementia should be quantified using measures beyond just distance visual acuity.

References:
  1. Smith JR, Huang AR, Zhou Y, et al. Vision Impairment and the Population Attributable Fraction of Dementia in Older Adults. JAMA Ophthalmol. 2024;142:900-908; doi:10.1001/jamaophthalmol.2024.3131
  2. US Department of Health and Human Services. National plan to address Alzheimer’s disease: 2021 update. Accessed April 10, 2023. https://aspe.hhs.gov/sites/default/files/documents/66904c18bb1f0843c3c113d7099e98c1/napa-national-plan-2021-update.pdf
  3. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
  4. National Academies of Sciences E. Medicine. Preventing cognitive decline and dementia: a way forward. The National Academies Press; 2017.
  5. Kuźma E, Littlejohns TJ, Khawaja AP, Llewellyn DJ, Ukoumunne OC, Thiem U. Visual impairment, eye diseases, and dementia risk: a systematic review and meta-analysis. J Alzheimers Dis. 2021;83:1073-1087. doi:10.3233/JAD-210250
  6. Shang X, Zhu Z, Wang W, Ha J, He M. The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis. Ophthalmology. 2021;128:1135-1149. doi:10.1016/j.ophtha.2020.12.029
  7. Nagarajan N, Assi L, Varadaraj V, et al. Vision impairment and cognitive decline among older adults: a systematic review. BMJ Open. 2022;12:e047929. doi:10.1136/bmjopen-2020-047929
  8. Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9::e489-e551. doi:10.1016/S2214-109X(20)30488-5
  9. Flaxman AD, Wittenborn JS, Robalik T, et al; Vision and Eye Health Surveillance System study group. Prevalence of visual acuity loss or blindness in the US: a Bayesian meta-analysis. JAMA Ophthalmol. 2021;139:717-723. doi:10.1001/jamaophthalmol.2021.0527
  10. Killeen OJ, De Lott LB, Zhou Y, et al. Population prevalence of vision impairment in US adults 71 years and older: the National Health and Aging Trends Study. JAMA Ophthalmol. 2023;141:197-204. doi:10.1001/jamaophthalmol.2022.5840
  11. Freedman VA, Kasper JD. Cohort profile: the National Health and Aging Trends Study (NHATS). Int J Epidemiol. 2019;48:1044-1045g. doi:10.1093/ije/dyz109
Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.